CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment

JUŘICA, Jan, Richard BARTEČEK, Ondřej ZENDULKA, Tomáš KAŠPÁREK, Eva PINDUROVÁ and Alexandra ŠULCOVÁ. CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment. In The 61th Czech-Slovak Pharmacological days and EPHAR symposium. 2011. ISBN 978-80-7399-770-0.

Basic information

• Original name: CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
• Name in Czech: Stanovení fenoptypu a genotypu CYP2D6 s ohledem na predikci terapeutické odpovědi u prvních epizod schizofrenie
• Name (in English): CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
• Authors: JUŘICA, Jan (203 Czech Republic, guarantor, belonging to the institution), Richard BARTEČEK (203 Czech Republic, belonging to the institution), Ondřej ZENDULKA (203 Czech Republic, belonging to the institution), Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution), Eva PINDUROVÁ (203 Czech Republic) and Alexandra ŠULCOVÁ (203 Czech Republic, belonging to the institution).
• Edition: The 61th Czech-Slovak Pharmacological days and EPHAR symposium, 2011.

Other information

• Original language: Czech
• Type of outcome: Conference abstract
• Field of Study: 30104 Pharmacology and pharmacy
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14110/11:00056990
• Organization unit: Faculty of Medicine
• ISBN: 978-80-7399-770-0
• Keywords (in Czech): CYP2D6; genotyp; fenotyp; schizofrenie
• Keywords in English: CYP2D6; genotype; phenotype; schizophrenia

Abstract

Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.

Abstract (in English)

Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.

Links

• NS9676, research and development project: Name: Vliv farmakogenetických a farmakokinetických faktorů na účinnost a bezpečnost terapie prvních epizod schizofrenie

Investor: Ministry of Health of the CR